ANVS-25001 Study:Evaluating Buntanetap for Early Alzheimer's Disease
The ANVS-25001 study is a Phase 3 clinical trial sponsored by Annovis Bio. It investigates the efficacy and safety of Buntanetap (Posiphen) in improving cognition and function in people with early Alzheimer's disease. This oral treatment targets neurotoxic proteins to potentially slow disease progression.
Study highlights
Key information about the ANVS-25001 study
- 55 to 85 years old
- Early Alzheimer's Disease
- Study partner (friend or family) available
- Daily Oral Medication
- Study zone: Central Florida and Greater Philadelphia
Study goal and design
Targeting neurotoxic proteins to improve cognition
The ANVS-25001 study is a Phase 3, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Buntanetap (Posiphen) in patients with early Alzheimer's disease.
Buntanetap is an orally administered drug designed to inhibit the production of neurotoxic proteins (amyloid-beta, tau, and alpha-synuclein) that accumulate in the brain and impair function. The study aims to determine if the drug can improve cognition and daily functioning over an 18-month period.
Study-related care and support
Regular monitoring and safety assessments
While contributing to research, participants receive:
- The possibility to receive Buntanetap investigational study medication
- Regular medical check-ups and safety monitoring
- Cognitive assessments (ADAS-Cog13, ADCS-iADL)
- Volumetric MRI brain scans at months 6 and 18
All medical and travel costs related to the study are covered.
Volunteer journey
A structured research experience
Express your interest
Answer a questionnaire to check preliminary criteria (Age 55-85, Early AD diagnosis).
Meet the study team
Complete screening assessments including MMSE, CDR, and blood biomarkers to confirm eligibility.
Begin treatment (or placebo)
Take the study medication (or placebo) orally, once daily for 18 months.
Continue the study
Attend clinic visits for health checks and MRI scans to monitor progress and safety.
Ready to get involved?Join the ANVS-25001 study.
Contribute to progress, support research, help others, and care for your health.